Walleye Capital
VINC

Walleye Capital’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Walleye Capital’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,752
Closed -$136K – 6014
2023
Q4 		$136K Hold
5,752
– – ﹤0.01% 3894
2023
Q3 		$118K Sell
5,752
-1,000
-15% -$19.4K ﹤0.01% 3858
2023
Q2 		$176K Buy
+6,752
New +$193K ﹤0.01% 3155

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's VINC Position: Q1 2024 in Review

Walleye Capital sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2024, closing a stake of 5,752 shares — an estimated $136K sold.

Walleye Capital first reported a position in VINC in Q2 2023 and held it in 3 quarters. The position peaked at $176K in Q2 2023. 40 funds tracked by Wall St. Rank hold VINC as of Q1 2024.

  • Walleye Capital reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Walleye Capital sold 5,752 Vincerx Pharma, Inc. Common Stock shares in Q1 2024, an estimated $136K.
  • Walleye Capital first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2023 and held it in 3 quarters.
  • Walleye Capital's Vincerx Pharma, Inc. Common Stock position peaked at $176K in Q2 2023.
  • 40 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.